Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:46:57.338Z.
Calculation as of: 2026-10-06T19:46:57.338Z.
Quote observation: 2026-10-06T19:45:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6caa0376099c5ebdf209f9b018955c4d65987c3db8176dc1b5ff0a1c5aca19bf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Bright Minds Biosciences Inc.
Market Cap
$474.58M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$477.04M
Price/OCF Ratio
N/A
TTM Avg
25.67
3Y Avg
25.67
5Y Avg
25.67
Market Cap
$469.39M
Price/OCF Ratio
N/A
TTM Avg
112.22
3Y Avg
112.22
5Y Avg
112.22
Market Cap
$468.55M
Price/OCF Ratio
193.85
TTM Avg
142.73
3Y Avg
100.92
5Y Avg
100.92
Market Cap
$484.06M
Price/OCF Ratio
11.76
TTM Avg
8.06
3Y Avg
6.53
5Y Avg
6.99
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bright Minds Biosciences Inc. (DRUG) | $474.58M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $477.04M | N/A | 25.67 | 25.67 | 25.67 |
| Arvinas, Inc. (ARVN)vs › | $471.33M | N/A | 5.46 | 5.49 | 10.64 |
| Alpha Teknova, Inc. (TKNO)vs › | $469.39M | N/A | 112.22 | 112.22 | 112.22 |
| Kamada Ltd. (KMDA)vs › | $468.77M | 13.02 | 15.89 | 21.03 | 20.03 |
| Cerus Corporation (CERS)vs › | $468.55M | 193.85 | 142.73 | 100.92 | 100.92 |
| Sight Sciences, Inc. (SGHT)vs › | $467.11M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $484.06M | 11.76 | 8.06 | 6.53 | 6.99 |
| Evolus, Inc. (EOLS)vs › | $486.34M | N/A | N/A | N/A | N/A |
| Oculis Holding AG (OCS)vs › | $491.66M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
